Tango Therapeutics, Inc.TNGXNASDAQ
Loading
R&D Expense Growth AcceleratingAccelerating
Percentile Rank65
3Y CAGR+102.2%
5Y CAGR-9.1%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
+102.2%/yr
Quarterly compound
5Y CAGR
-9.1%/yr
Recent acceleration
Percentile
P65
Within normal range
vs 5Y Ago
0.6x
Contraction
Streak
2 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 9.98% |
| Q3 2025 | -5.97% |
| Q2 2025 | -11.69% |
| Q1 2025 | 7.38% |
| Q4 2024 | 2.03% |
| Q3 2024 | -13.95% |
| Q2 2024 | 1.55% |
| Q1 2024 | 21.46% |
| Q4 2023 | 15.43% |
| Q3 2023 | -5.31% |
| Q2 2023 | 2.25% |
| Q1 2023 | -3.62% |
| Q4 2022 | 1.21% |
| Q3 2022 | 21.07% |
| Q2 2022 | -2.42% |
| Q1 2022 | 12.46% |
| Q4 2021 | -1.32% |
| Q3 2021 | 14.91% |
| Q2 2021 | 27.19% |
| Q1 2021 | -0.42% |
| Q4 2020 | 16.07% |
| Q3 2020 | 16.61% |
| Q2 2020 | 2.84% |
| Q1 2020 | 0.00% |